Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Dellabona

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Immunotherapy|July 20, 2010
T helper 17 T cells do good for cancer immunotherapyGlenda Canderan, Paolo Dellabona
European Journal of Immunology|July 11, 2017
Of self-lipids, CD1-restricted T cells, and contact sensitizationGiulia Casorati, Paolo Dellabona
Molecular Immunology|October 12, 2018
Potential advantages of CD1-restricted T cell immunotherapy in cancerMichela Consonni, Paolo Dellabona, Giulia Casorati
Bio-Protocol|July 14, 2023
Primary Mouse Invariant Natural Killer T (iNKT) Cell Purification and TransductionGloria Delfanti, Paolo Dellabona, Giulia Casorati
European Journal of Immunology|May 1, 2014
iNKT-cell help to B cells: a cooperative job between innate and adaptive immune responsesPaolo Dellabona, Sergio Abrignani, Giulia Casorati
Oncoimmunology|June 28, 2012
Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantationGiulia Casorati, Claudia de Lalla, Paolo Dellabona
Molecular Immunology|February 14, 2021
Exploiting CD1-restricted T cells for clinical benefitMark A Exley, Paolo Dellabona, Giulia Casorati
Frontiers in Medicine|May 26, 2022
Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive MicroenvironmentGloria Delfanti, Paolo Dellabona, Giulia Casorati, et al.
Methods in Cell Biology|July 19, 2025
Human and mouse iNKT cell expansion and engineering with viral vectorsGloria Delfanti, Paolo Dellabona, Giulia Casorati, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 3, 2008
B cell helper assaysSergio Abrignani, Elena Tonti, Giulia Casorati, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Immunotherapy|July 20, 2010
T helper 17 T cells do good for cancer immunotherapyGlenda Canderan, Paolo Dellabona
European Journal of Immunology|July 11, 2017
Of self-lipids, CD1-restricted T cells, and contact sensitizationGiulia Casorati, Paolo Dellabona
Molecular Immunology|October 12, 2018
Potential advantages of CD1-restricted T cell immunotherapy in cancerMichela Consonni, Paolo Dellabona, Giulia Casorati
Bio-Protocol|July 14, 2023
Primary Mouse Invariant Natural Killer T (iNKT) Cell Purification and TransductionGloria Delfanti, Paolo Dellabona, Giulia Casorati
European Journal of Immunology|May 1, 2014
iNKT-cell help to B cells: a cooperative job between innate and adaptive immune responsesPaolo Dellabona, Sergio Abrignani, Giulia Casorati
Oncoimmunology|June 28, 2012
Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantationGiulia Casorati, Claudia de Lalla, Paolo Dellabona
Molecular Immunology|February 14, 2021
Exploiting CD1-restricted T cells for clinical benefitMark A Exley, Paolo Dellabona, Giulia Casorati
Frontiers in Medicine|May 26, 2022
Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive MicroenvironmentGloria Delfanti, Paolo Dellabona, Giulia Casorati, et al.
Methods in Cell Biology|July 19, 2025
Human and mouse iNKT cell expansion and engineering with viral vectorsGloria Delfanti, Paolo Dellabona, Giulia Casorati, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 3, 2008
B cell helper assaysSergio Abrignani, Elena Tonti, Giulia Casorati, et al.
Pageof 9